The Microbiota in Hematologic Malignancies

• Published in: Current treatment options in oncology Vol. 21; no. 1; p. 2
• Main Authors: Song, Yajing, Himmel, Bryan, Öhrmalm, Lars, Gyarmati, Peter
• Format: Journal Article
• Language: English
• Published: New York Springer US 2020
• Subjects: Leukemia (PH Wiernik; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Oncology; Section Editor; Topical Collection on Leukemia; Metagenomics; Microbiota; Hematologic malignancies; Bloodstream infection; Leukemia
• ISSN: 1527-2729; 1534-6277; 1534-6277
• DOI: 10.1007/s11864-019-0693-7

Opinion statement There are approximately 1.2 million new hematologic malignancy cases resulting in ~ 690,000 deaths each year worldwide, and hematologic malignancies remain the most commonly occurring cancer in children. Even though advances in anticancer treatment regimens in recent decades have considerably improved survival rates, their cytotoxic effects and the resulting long-term complications pose a significant burden on the patients and the health care system. Therefore, non-toxic treatment modalities are needed to decrease side effects. The human body is the host to approximately 40 trillion microbes, known as the human microbiota. The large majority of the microbiota is located in the gastrointestinal tract, and is primarily composed of bacteria. The microbiota plays several important physiological roles, ranging from digestive functions to immunological and neural development. Investigating the microbiota in patients with hematologic malignancies has several important implications. The microbiota affects hematopoiesis, and influences the efficacies of chemotherapy and antimicrobial treatments. Determination of the microbiota composition and diversity could be an important part of risk stratification in the future, and may also take part to personalize antimicrobial treatments. Modulation of the microbiota via probiotics or fecal transplant can potentially be involved in reducing side effects of chemotherapy, and eliminating multiple drug resistant strains in patients with hematologic malignancies.